Roland Kocijan1, Stephanie Finzel2, Matthias Englbrecht2, Klaus Engelke3, Juergen Rech2, Georg Schett2. 1. Department of Internal Medicine 3 and Institute of Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany St. Vincent Hospital - Medical Department II, The VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Austria. 2. Department of Internal Medicine 3 and Institute of Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany. 3. Institute of Medical Physics, University of Erlangen-Nuremberg, Erlangen, Germany.
Abstract
OBJECTIVE: To investigate whether trabecular and cortical bone structure differ between patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). So far, no study has performed a detailed comparative analysis of bone structure in patients with RA and PsA. METHODS: 110 patients (60 RA, 50 PsA) received high-resolution peripheral quantitative CT of the distal radius. Demographic and disease-specific parameters including anti-rheumatic treatment, bone erosion status and previous fractures were recorded. RESULTS: RA and PsA patients were comparable in age, gender, body mass index, disease duration, disease activity, functional status, antirheumatic treatment and bone erosion status. No significant differences were found for volumetric bone mineral density (BMD), including total BMD (300±77 vs 316±62 mgHA/cm(3)), trabecular BMD (152±46 vs 165±40 mgHA/cm(3)) and cortical BMD (787±113 vs 818±76 mgHA/cm(3)) when comparing RA patients to PsA patients, respectively. However, in contrast to seronegative RA, seropositive RA showed significantly reduced trabecular BMD (p=0.007), bone volume per tissue volume (p=0.007) and trabecular number (p=0.044), as well as a strong trend towards higher trabecular inhomogeneity compared to PsA patients. In the regression analysis, higher age, female gender and presence of autoantibodies were independently associated with trabecular bone loss. CONCLUSIONS: Seropositive RA exhibits more profound changes in trabecular bone architecture than seronegative RA or PsA. The data support the concept that seropositive RA is a disease entity that is distinct from seronegative RA and PsA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: To investigate whether trabecular and cortical bone structure differ between patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). So far, no study has performed a detailed comparative analysis of bone structure in patients with RA and PsA. METHODS: 110 patients (60 RA, 50 PsA) received high-resolution peripheral quantitative CT of the distal radius. Demographic and disease-specific parameters including anti-rheumatic treatment, bone erosion status and previous fractures were recorded. RESULTS:RA and PsA patients were comparable in age, gender, body mass index, disease duration, disease activity, functional status, antirheumatic treatment and bone erosion status. No significant differences were found for volumetric bone mineral density (BMD), including total BMD (300±77 vs 316±62 mgHA/cm(3)), trabecular BMD (152±46 vs 165±40 mgHA/cm(3)) and cortical BMD (787±113 vs 818±76 mgHA/cm(3)) when comparing RApatients to PsA patients, respectively. However, in contrast to seronegative RA, seropositive RA showed significantly reduced trabecular BMD (p=0.007), bone volume per tissue volume (p=0.007) and trabecular number (p=0.044), as well as a strong trend towards higher trabecular inhomogeneity compared to PsA patients. In the regression analysis, higher age, female gender and presence of autoantibodies were independently associated with trabecular bone loss. CONCLUSIONS: Seropositive RA exhibits more profound changes in trabecular bone architecture than seronegative RA or PsA. The data support the concept that seropositive RA is a disease entity that is distinct from seronegative RA and PsA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Bone Mineral Density; Osteoporosis; Psoriatic Arthritis; Rheumatoid Arthritis
Authors: Joshua F Baker; Jin Long; Sogol Mostoufi-Moab; Michele Denburg; Erik Jorgenson; Prerna Sharma; Babette S Zemel; Elena Taratuta; Said Ibrahim; Mary B Leonard Journal: J Rheumatol Date: 2017-09-15 Impact factor: 4.666
Authors: C A F Zerbini; P Clark; L Mendez-Sanchez; R M R Pereira; O D Messina; C R Uña; J D Adachi; W F Lems; C Cooper; N E Lane Journal: Osteoporos Int Date: 2016-10-31 Impact factor: 4.507
Authors: Cristina Regueiro; Ana M Ortiz; Maria Dolores Boveda; Santos Castañeda; Isidoro Gonzalez-Alvaro; Antonio Gonzalez Journal: PLoS One Date: 2018-08-17 Impact factor: 3.240
Authors: Serena Bugatti; Barbara Vitolo; Roberto Caporali; Carlomaurizio Montecucco; Antonio Manzo Journal: Biomed Res Int Date: 2014-04-29 Impact factor: 3.411
Authors: Anna Neumann; Judith Haschka; Arnd Kleyer; Louis Schuster; Matthias Englbrecht; Andreas Berlin; Camille P Figueiredo; David Simon; Christian Muschitz; Roland Kocijan; Heinrich Resch; Jürgen Rech; Georg Schett Journal: Arthritis Res Ther Date: 2018-08-30 Impact factor: 5.156